Experience with intramuscular glucagon for infants with early neonatal hypoglycemia

Tatiana Smolkin, Joanne S. Makhoul, Razan Elias, Fadi Farah, Amir Kugelman, Mariam Dallashi, Imad R. Makhoul

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Parenteral options for treating neonatal hypoglycemia (NH) include: intramuscular (i.m.) glucagon or intravenous (i.v.) glucose 10%. So far, the role of i.m. glucagon in treating NH has not been adequately assessed. We retrospectively studied 236 neonates with NH. One hundred and twenty-one infants received oral glucose-fortified-milk-based formula (OGFM) and their blood glucose level (BGL) was maintained thereafter. Two groups of infants required intervention: (a) OGFM + i.m. glucagon (n = 77, 32.6%) and (b) OGFM + i.v. glucose bolus (n = 38, 16.1%). BGL1, BGL2 and BGL3 denote pre-treatment BGL, 2–2.5 h post-treatment and BGL within 2.5–4 h post-treatment; respectively. The two groups were compared regarding two outcome measures: Outcome no. 1: BGL2 ≥ 45 mg/dL and outcome no. 2: BGL3 ≥ 45 mg/dL. Compared to i.v. glucose, the i.m. glucagon group had significantly more infants with BGL2 ≥ 45 mg/dL (40% vs. 76%, p = 0.028), and marginal significant difference regarding BGL3 ≥ 45 mg/dL (62% vs. 77%, p = 0.08). Univariate analysis showed that i.m. glucagon, male gender, vacuum extraction, cesarean delivery and one or more NH risk factors were significantly associated with outcome measure no. 1. I.m. glucagon, small for gestational age status, cesarean delivery, BGL1 and NH risk factors were associated with outcome measure no. 2. Multi-variate analysis showed that i.m. glucagon was significantly and independently associated with BGL2 ≥ 45 mg/dL. I.m. glucagon is worth consideration as a treatment option for NH.

Original languageEnglish
Pages (from-to)1023-1026
Number of pages4
JournalJournal of Pediatric Endocrinology and Metabolism
Volume32
Issue number9
DOIs
StatePublished - 25 Sep 2019

Bibliographical note

Publisher Copyright:
© 2019 Walter de Gruyter GmbH. All rights reserved.

Keywords

  • glucagon
  • hypoglycemia
  • newborn

Fingerprint

Dive into the research topics of 'Experience with intramuscular glucagon for infants with early neonatal hypoglycemia'. Together they form a unique fingerprint.

Cite this